作者
Yelena Y Janjigian, Johanna Bendell, Emiliano Calvo, Joseph W Kim, Paolo A Ascierto, Padmanee Sharma, Patrick A Ott, Katriina Peltola, Dirk Jaeger, Jeffry Evans, Filippo De Braud, Ian Chau, Christopher T Harbison, Cecile Dorange, Marina Tschaika, Dung T Le
发表日期
2018/10/10
期刊
Journal of Clinical Oncology
卷号
36
期号
28
页码范围
2836
出版商
American Society of Clinical Oncology
简介
Purpose
Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refractory esophagogastric cancers.
学术搜索中的文章
YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto… - Journal of Clinical Oncology, 2018